BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2025)
BridgeBio Pharma (BBIO) has disclosed Receivables - Net for 4 consecutive years, with $139.4 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 2853.07% to $139.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.4 million through Dec 2025, up 2853.07% year-over-year, with the annual reading at $139.4 million for FY2025, 2853.07% up from the prior year.
- Receivables - Net hit $139.4 million in Q4 2025 for BridgeBio Pharma, up from $116.5 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $139.4 million in Q4 2025 to a low of $1.2 million in Q2 2021.
- Historically, Receivables - Net has averaged $65.1 million across 4 years, with a median of $76.9 million in 2025.
- Biggest five-year swings in Receivables - Net: surged 169.67% in 2024 and later soared 2853.07% in 2025.
- Year by year, Receivables - Net stood at $1.2 million in 2021, then surged by 44.35% to $1.8 million in 2023, then soared by 169.67% to $4.7 million in 2024, then skyrocketed by 2853.07% to $139.4 million in 2025.
- Business Quant data shows Receivables - Net for BBIO at $139.4 million in Q4 2025, $116.5 million in Q3 2025, and $76.9 million in Q2 2025.